Skip to main content

Cue Biopharma, Inc. (CUE)

NASDAQ: CUE · IEX Real-Time Price · USD
12.17 0.19 (1.59%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap386.53M
Revenue (ttm)7.16M
Net Income (ttm)-46.88M
Shares Out31.76M
EPS (ttm)-1.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume162,504
Open11.99
Previous Close11.98
Day's Range11.71 - 12.38
52-Week Range9.65 - 18.42
Beta1.77
AnalystsStrong Buy
Price Target29.83 (+145.1%)
Earnings DateNov 16, 2021

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 ...

IndustryBiotechnology
IPO DateJan 2, 2018
CEODaniel Passeri
Employees50
Stock ExchangeNASDAQ
Ticker SymbolCUE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Cue Biopharma stock is "Strong Buy." The 12-month stock price forecast is 29.83, which is an increase of 145.11% from the latest price.

Price Target
$29.83
(145.11% upside)
Analyst Consensus: Strong Buy

News

Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

2 weeks ago - GlobeNewsWire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

4 weeks ago - GlobeNewsWire

Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for t...

Research demonstrates Immuno-STAT™ Biologics lead to direct and selective activation and expansion of anti-viral cytotoxic T cells in vivo specific for human immunodeficiency virus (HIV) and cytomegalov...

1 month ago - GlobeNewsWire

Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT...

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage...

2 months ago - GlobeNewsWire

Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio

2 months ago - GlobeNewsWire

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansi...

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage ...

3 months ago - GlobeNewsWire

Cue Biopharma to Host Business Update Call and Webcast

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

3 months ago - GlobeNewsWire

Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

4 months ago - GlobeNewsWire

Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

5 months ago - GlobeNewsWire

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ ...

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

5 months ago - GlobeNewsWire

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

6 months ago - GlobeNewsWire

Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform P...

CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage a...

6 months ago - GlobeNewsWire

Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow...

6 months ago - Zacks Investment Research

Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study

Cue Biopharma Inc (NASDAQ: CUE) has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive re...

6 months ago - Benzinga

Market Update: The 10 Most Volatile Stocks Today

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on In...

6 months ago - InvestorPlace

Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selective...

8 months ago - GlobeNewsWire

Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare ...

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selective...

8 months ago - GlobeNewsWire

Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selective...

9 months ago - GlobeNewsWire

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

9 months ago - GlobeNewsWire

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development

Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs

9 months ago - GlobeNewsWire

7 Stocks With Insider Buying This Week Worth A Look

Insider buying is often a profitable signal for bulls. Insiders only buy for one reason: they believe their company's stock is going higher.

10 months ago - InvestorPlace

Do Options Traders Know Something About Cue Biopharma (CUE) Stock We Don't?

Investors need to pay close attention to Cue Biopharma (CUE) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research